Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-10-25
2008-10-07
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024100, C536S023100, C536S024500, C435S006120
Reexamination Certificate
active
07432250
ABSTRACT:
Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2′-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins.
REFERENCES:
patent: 3687608 (1972-08-01), Merigan et al.
patent: 4373071 (1983-02-01), Itakura
patent: 4401796 (1983-08-01), Itakura
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4507433 (1985-03-01), Miller et al.
patent: 4720483 (1988-01-01), Jansz et al.
patent: 4757141 (1988-07-01), Fung et al.
patent: 4812512 (1989-03-01), Buendia et al.
patent: 4908405 (1990-03-01), Bayer et al.
patent: 5013830 (1991-05-01), Ohtsuka et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5082934 (1992-01-01), Saba et al.
patent: 5130302 (1992-07-01), Spielvogel
patent: 5142047 (1992-08-01), Summerton et al.
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5177198 (1993-01-01), Spielvogel et al.
patent: 5223618 (1993-06-01), Cook et al.
patent: 5235033 (1993-08-01), Summerton et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264562 (1993-11-01), Matteucci
patent: 5264564 (1993-11-01), Matteucci
patent: 5359044 (1994-10-01), Cook et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5378825 (1995-01-01), Cook et al.
patent: 5386023 (1995-01-01), Sanghvi et al.
patent: 5391667 (1995-02-01), Dellinger
patent: 5403711 (1995-04-01), Walder et al.
patent: 5424413 (1995-06-01), Hogan et al.
patent: 5457191 (1995-10-01), Cook et al.
patent: 5459255 (1995-10-01), Cook et al.
patent: 5466786 (1995-11-01), Buhr et al.
patent: 5476925 (1995-12-01), Letsinger et al.
patent: 5484908 (1996-01-01), Froehler et al.
patent: 5489677 (1996-02-01), Sanghvi et al.
patent: 5506212 (1996-04-01), Hoke et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5506351 (1996-04-01), McGee
patent: 5508270 (1996-04-01), Baxter et al.
patent: 5514786 (1996-05-01), Cook et al.
patent: 5519134 (1996-05-01), Acevedo et al.
patent: 5539083 (1996-07-01), Cook et al.
patent: 5561043 (1996-10-01), Cantor et al.
patent: 5612469 (1997-03-01), Goodchild
patent: 5614617 (1997-03-01), Cook et al.
patent: 5631148 (1997-05-01), Urdea
patent: 5639873 (1997-06-01), Barascut et al.
patent: 5719271 (1998-02-01), Cook et al.
patent: 5760202 (1998-06-01), Cook et al.
patent: 5861493 (1999-01-01), Cook et al.
patent: 5891684 (1999-04-01), Usman et al.
patent: 5898031 (1999-04-01), Crooke et al.
patent: 5955443 (1999-09-01), Bennett et al.
patent: 5962425 (1999-10-01), Walder et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 6037463 (2000-03-01), Uhlmann et al.
patent: 6087484 (2000-07-01), Goodchild
patent: 6107094 (2000-08-01), Crooke
patent: 6133246 (2000-10-01), McKay et al.
patent: 6210892 (2001-04-01), Bennett et al.
patent: 6222025 (2001-04-01), Cook et al.
patent: 6262036 (2001-07-01), Arnold, Jr. et al.
patent: 6274723 (2001-08-01), Nilsen
patent: 6506559 (2003-01-01), Fire et al.
patent: 6573072 (2003-06-01), Goodchild
patent: 6818759 (2004-11-01), Beigelman et al.
patent: 6849726 (2005-02-01), Usman et al.
patent: 7022828 (2006-04-01), McSwiggen
patent: 2003/0125241 (2003-07-01), Wissenbach et al.
patent: 2003/0139585 (2003-07-01), Uhlmann et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0206887 (2003-11-01), Morrissey et al.
patent: 2004/0029275 (2004-02-01), Brown et al.
patent: 2004/0146867 (2004-07-01), Slattum et al.
patent: 2005/0142535 (2005-06-01), Damha et al.
patent: 101 00 588 (2002-07-01), None
patent: 0 266 168 (1988-05-01), None
patent: 339842 (1989-11-01), None
patent: 2-264792 (1990-10-01), None
patent: WO92/07065 (1992-04-01), None
patent: WO92/20822 (1992-11-01), None
patent: WO92/20823 (1992-11-01), None
patent: WO92/22651 (1992-12-01), None
patent: WO 93/07883 (1993-04-01), None
patent: WO 94/01550 (1994-01-01), None
patent: WO 94/02498 (1994-02-01), None
patent: WO94/02499 (1994-02-01), None
patent: WO94/02501 (1994-02-01), None
patent: WO94/17093 (1994-08-01), None
patent: WO 96/07392 (1996-03-01), None
patent: WO 97/46570 (1997-12-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 02/44321 (2002-06-01), None
Ausubel, et al., Eds., Current Protocols in Molecular Biology, 1988, Wiley & Sons, New York.
Beaucage S. and Iyer, R., “Advances in the synthesis of oligonucleotides by the phosphoramidite approach”,Tetrahedron Letters, 1992, 48, 2223-2311.
Beaucage S. and Iyer, R., “The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications”,Tetrahedron, 1993, 49, 6123-6194.
Bhat, et al., “A Simple and Convenient Method for the Selective N-Acylations of Cytosine Nucleosides”,Nucleosides and Nucleotides, 1989, 8, 179-183.
Crooke, S.T. and Bennett, C.F., “Progress in Antisense Oligonucleotide Therapeutics”,Annu. Rev. Pharmacol. Toxicol., 1996, 36, 107-129.
Crooke, et al., “Kinetic characteristics ofEscherichia coliRNase H1: cleavage of various antisense oligonucleotide-RNA duplexes”,Biochem. J., 1995, 312, 599-608.
Dagle, et al., “Targeted degradation of mRNA inXenopus oocytesand embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis”,Nucleic Acids Research, 1990, 18, 4751-4757.
Dagle, et al., “Pathways of Degradation and Mechanism of Action of Antisense Oligonucleotides inXenopus laevisEmbryos”,Antisense Res. And Dev., 1991, 1, 11-20.
Dagle, et al., “Physical properties of oligonucleotides containing phosphoramidate-modified internucleoside linkages”,Nucleic Acids Research, 1991, 19, 1805-1810.
Englisch, U. And Gauss, D.H., “Chemically Modified Oligonucleotides as Probes and Inhibitors”,Angewandt Chemie, International Edition Engl., 1991, 30, 613-629.
Haeuptle and Dobberstein, “Translation arrest by oligonucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length”,Nucleic Acids Res., 1986, 14, 1427-1448.
Eder, P.S. and Walder, J.A., “Ribonuclease H from K562 Human Erythroleukemia Cells”,J. Biol. Chem., 1991, 266, 6472-6479.
Kawasaki, et al., “Uniformly Modified 2′-Deoxy-2′-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets”,J. Med. Chem., 1993, 36, 831-841.
Kawasaki, et al., “Synthesis and Biophysical Studies of 2′-dRIBO-2′-F Modified Oligonucleotides”, ISIS Pharmaceuticals, Inc., 2280 Faraday Avenue, Carlsbad, CA 92008, USA.
Martin, “Ein neuer Zugang zu 2′-O-Alkylribonucleosiden und Eigenschaften deren Oligonucleotide”,Helv. Chim. Acta., 1995, 78, 486-504.
Monia, et al., “Selective Inhibition of Mutant Ha-ras mRNA Expression by Antisense Oligonucleotides”,J. Biol. Chem., 1992, 267, 19954-19962.
Monia, et al., “Evaluation of 2′-Modified Oligonucleotides Containing 2′-Deoxy Gaps as Antisense Inhibitors of Gene Expression”,J. Biol. Chem., 1993, 268. 14514-14522.
Reese, C.B., et al., “4-(1,2,4-Triazol-1-yl)-and 4-(3-Nitro-1,2,4-triazol-1-yl)
Isis Pharmaceuticals , Inc.
Isis Pharmaceuticals Inc. Patent Department
McGarry Sean R
LandOfFree
Oligoribonucleotides and ribonucleases for cleaving RNA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligoribonucleotides and ribonucleases for cleaving RNA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligoribonucleotides and ribonucleases for cleaving RNA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3995964